Skip to content

NeuBase Therapeutics, Inc.

  • About
    • Overview
    • Senior Management
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • Additional Indications
  • Technology
    • Overview
    • Key Features
    • PATrOL™ Platform
    • Publications
  • Patients
  • Partnering
  • Investors
  • Contact Us
  • Twitter
  • LinkedIn
Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents

Press Releases

  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

NeuBase Therapeutics Strengthens Senior Management Team with Appointment of Industry Veteran William Mann, Ph.D., MBA as Chief Operating Officer

Jul 28, 2020 8:00am EDT

NeuBase Therapeutics Added to Russell 3000® and Russell Microcap® Indexes

Jun 29, 2020 9:00am EDT

NeuBase Therapeutics Reports Financial Results for the Second Fiscal Quarter of 2020

May 14, 2020 4:05pm EDT

NeuBase Therapeutics to Present at Upcoming Investor Conferences in May 2020

May 11, 2020 8:00am EDT

NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Apr 30, 2020 4:05pm EDT

NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock

Apr 28, 2020 9:44am EDT

NeuBase Therapeutics Announces Proposed Public Offering of Common Stock

Apr 27, 2020 4:01pm EDT

NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform

Mar 31, 2020 7:00am EDT

NeuBase Therapeutics Reports Financial Results for the First Fiscal Quarter of 2020

Mar 26, 2020 4:05pm EDT

NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 21, 2020 4:50pm EST
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    NeuBase Therapeutics, Inc.

    • About
    • Pipeline
    • Technology
    • Patients
    • Partnering
    • Investors
    • Contact Us
    NeuBase Therapeutics, Inc. 700 Technology Drive Pittsburgh, PA 15219
    info@neubasetherapeutics.com
    • Twitter
    • LinkedIn